Bone Density Loss on GLP-1 During Menopause: The Double Risk Nobody Warned You About

Menopause causes bone loss because estrogen — the hormone that keeps bone-building cells (osteoblasts) outpacing bone-resorbing cells (osteoclasts) — drops sharply. The Study of Women's Health Across the Nation (SWAN) followed more than 1,900 women through the menopause transition and found that bone mineral density (BMD) falls by roughly 0.018 g/cm² per year at the lumbar spine and 0.010 g/cm² per year at the femoral neck during the year before and two years after the final menstrual period. That's about a 2% annual loss at the spine during the fastest window. Over the first 5–7 years after menopause, the average woman loses up to 20% of her lifetime bone density. Smaller-framed women, women with low body weight, and women of Asian or Caucasian descent tend to lose more. The cumulative effect is why one in two women over 50 will break a bone due to osteoporosis in their lifetime, according to the Bone Health & Osteoporosis Foundation.

GLP-1 medications do not directly cause bone loss, but the rapid weight loss they produce can. Bone responds to mechanical loading — when you weigh less, your skeleton experiences less force, and bone density can decline as a result. A 2024 secondary analysis of the STEP 1 trial (semaglutide 2.4 mg) found that participants lost about 1% of total bone mineral density over 68 weeks compared to placebo. The SURMOUNT-1 trial of tirzepatide showed a similar trend, with greater BMD loss in those who lost more body weight. Importantly, this loss appears smaller than what is typically seen with bariatric surgery, and ongoing studies (including the STEP 9 bone health sub-analysis) suggest the rate slows once weight stabilizes. The key risk is in women who are already losing bone for hormonal reasons — combining two stressors compounds the problem.

If you're managing both menopause and a GLP-1 medication, our guide on [GLP-1s and HRT together: the Weill Cornell study](/blog/glp-1s-and-hrt-together-the-weill-cornell-study-and-what-it-means) explains why combining therapies may help offset some of these effects.

Researchers at Weill Cornell Medicine reported in 2024 that women taking HRT alongside GLP-1 medications lost slightly more weight than those on GLP-1s alone — and crucially, may experience better preservation of lean mass and bone density. The retrospective cohort followed more than 200 women on semaglutide or tirzepatide. While the study was not powered for fracture outcomes, the lean-mass signal is important: bone follows muscle. When you protect muscle through hormones and resistance training, you also tend to protect bone. This is one of the strongest practical arguments for considering HRT during midlife weight loss, especially if you are within 10 years of your final period — the so-called window of opportunity described in the KEEPS and ELITE trials.

You need 1.4 to 1.6 grams of protein per kilogram of body weight per day to support muscle and bone during GLP-1-driven weight loss in midlife. The 2025 advisory from obesity researchers (including those behind the SURMOUNT trials) recommended this higher range specifically because the standard 0.8 g/kg recommendation is built around sedentary, weight-stable adults — not women losing weight in midlife. For a 70 kg (155 lb) woman, that's roughly 100–110 g protein per day. Practical sources: Greek yogurt (15–17g per cup), eggs (6g each), cottage cheese (25g per cup), chicken breast (31g per 100g), tofu (10g per 100g), edamame (17g per cup). Distributing protein across 3–4 meals improves muscle protein synthesis better than one large dose. For specifics, see our [GLP-1 protein cheat sheet](/blog/the-glp-1-protein-cheat-sheet-30-foods-under-200-calories).

Resistance training and weight-bearing impact exercise build bone — gentle walking alone does not, especially during menopause. The LIFTMOR trial (Watson et al., JBMR 2018) showed that postmenopausal women with low bone mass who did 8 months of high-intensity resistance and impact training (heavy deadlifts, overhead press, jumps) gained spine BMD by 2.9% and femoral neck BMD by 0.3%, while the control group lost bone. A typical week should include resistance training 2–3 times (compound lifts — squats, deadlifts, rows, presses), 1–2 sessions of impact work (jumping, hopping, plyometrics if joints allow), and walking on rest days. Working with a trainer for the first 4–6 weeks is one of the highest-ROI investments you can make in midlife. Our deeper guide on [strength training on GLP-1: muscle preservation protocol](/blog/strength-training-on-glp-1-muscle-preservation-protocol) covers the specifics for women on these medications.

Yes — if you are perimenopausal or postmenopausal and considering or starting GLP-1 therapy, a baseline DEXA scan is reasonable. DEXA (dual-energy X-ray absorptiometry) measures BMD at the hip and spine and provides a T-score that compares your bone density to a young healthy reference. The U.S. Preventive Services Task Force recommends routine DEXA at age 65, but the International Society for Clinical Densitometry suggests earlier screening for women with risk factors — including early menopause, low BMI, family history of osteoporosis, or planned significant weight loss. A baseline scan gives you something to compare against if you lose 15–20% of body weight on a GLP-1. Many providers will order one if you ask. The scan takes about 15 minutes, involves very low radiation, and is typically covered by insurance with risk factors.

HRT is the most evidence-backed intervention for preserving bone density in postmenopausal women, and there's a strong rationale for using it alongside GLP-1s. The Women's Health Initiative (WHI) found that estrogen therapy reduced hip fracture risk by 34% over 5 years. The KEEPS and ELITE trials confirmed that starting HRT within 10 years of menopause preserves bone density without raising cardiovascular risk in healthy women. When you stack HRT with the GLP-1's metabolic benefits, you address two of the main midlife bone stressors at once: hormonal loss and mechanical unloading from weight loss. Decisions about HRT are individual — personal and family history matter — but the bone argument alone is strong for many women in the menopause window. Talk with a menopause-trained provider.

Aim for 1,200 mg of calcium per day (mostly from food) and 800–1,000 IU of vitamin D3 per day, per the Endocrine Society menopause guidelines. Vitamin K2 (180 mcg of MK-7) and magnesium glycinate (200–400 mg) have weaker but emerging evidence for bone. Avoid mega-dosing calcium supplements alone — meta-analyses have linked very high supplemental intake without vitamin D to a small increase in cardiovascular events. Food sources of calcium (Greek yogurt, sardines, leafy greens, fortified plant milks, tofu set with calcium sulfate) are safer and often better absorbed. Always check vitamin D status with a blood test before high-dose supplementation — many midlife women run low.

The bottom line is this: don't ignore bone. The narrative around GLP-1s has focused on appetite, weight, and cardiovascular outcomes, but skeletal health is the quiet long-term variable that determines whether you stay independent into your 70s and 80s. The combination of perimenopause, menopause, and rapid weight loss is real — but it's also highly modifiable. Eat enough protein. Lift heavy things. Get a baseline DEXA scan. Talk to a menopause-trained provider about HRT. Get your vitamin D checked. None of this is exotic. It's just consistent. And it's the difference between losing weight while losing bone, and losing weight while getting stronger. As always, this is general education — your provider needs to make individual decisions with you.